References
- Barkas F, Elisaf M. National hyperlipidemia management policies improve lipid target attainment in clinical practice. Curr Med Res Opin 2017;9:1-11. DOI: 10.1080/03007995.2017.1354833
- Kotseva K, Wood D, De Bacquer D, et al. EUROASPIRE IV: a European Society of Cardiology survey on the lifestyle, risk factor and therapeutic management of coronary patients from 24 European countries. Eur J Prev Cardiol 2016;23:636-48
- Yu W, Shi R, Li J, et al. Need for hyperlipidemia management policy reform in China: learning from the global experience. Curr Med Res Opin 2017;8:1-3. DOI: 10.1080/03007995.2017.1391082.
- Joint committee issued Chinese guideline for the management of dyslipidemia in adults. [2016 Chinese guideline for the management of dyslipidemia in adults]. Zhonghua Xin Xue Guan Bing Za Zhi 2016;44:833-53
- Catapano AL, Graham I, De Backer G, et al. 2016 ESC/EAS guidelines for the management of dyslipidaemias. Eur Heart J 2016;37:2999-3058
- Wu Y, Benjamin EJ, MacMahon S. Prevention and control of cardiovascular disease in the rapidly changing economy of China. Circulation 2016;133:2545-60
- Li Y-H, Ueng K-C, Jeng J-S, et al. 2017 Taiwan lipid guidelines for high risk patients. J Formos Med Assoc 2017;116:217-48
- Gitt AK, Lautsch D, Ferrieres J, et al. Cholesterol target value attainment and lipid-lowering therapy in patients with stable or acute coronary heart disease: results from the Dyslipidemia International Study II. Atherosclerosis 2017;266:158-66
- Gitt AK, Lautsch D, Ferrieres J, et al. Contemporary data on low-density lipoprotein cholesterol target value attainment and distance to target in a cohort of 57,885 statin-treated patients by country and region across the world. Data Brief 2016;9:616-20
- Park JE, Chiang CE, Munawar M, et al. Lipid-lowering treatment in hypercholesterolaemic patients: the CEPHEUS Pan-Asian survey. Eur J Prev Cardiol 2012;19:781-94
- Chan RH, Chan PH, Chan KK, et al. The CEPHEUS Pan-Asian survey: high low-density lipoprotein cholesterol goal attainment rate among hypercholesterolaemic patients undergoing lipid-lowering treatment in a Hong Kong regional centre. Hong Kong Med J 2012;18:395-406
- Lee VW, Chau RY, Cheung HY, et al. How low should we target the LDL goal to improve survival for acute coronary syndrome patients in Hong Kong? BMC Cardiovasc Disord 2015;15:117
- Stone NJ, Robinson JG, Lichtenstein AH, et al. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association task force on practice guidelines. J Am Coll Cardiol 2014;63:2889-934
- Tomlinson B, Chan P, Liu ZM. Statin responses in Chinese patients. J Atheroscler Thromb 2017; 21. DOI: 10.5551/jat.40204
- Rowlands G. Health literacy and public health: a framework for developing skills and empowering citizens. Perspect Public Health 2012;132:23-4
- Wu Y, Wang L, Cai Z, et al. Prevalence and risk factors of low health literacy: a community-based study in Shanghai, China. Int J Environ Res Public Health 2017;12. DOI: 10.3390/ijerph14060628
- Nielsen SF, Nordestgaard BG. Negative statin-related news stories decrease statin persistence and increase myocardial infarction and cardiovascular mortality: a nationwide prospective cohort study. Eur Heart J 2016;37:908-16
- Piepoli MF, Hoes AW, Agewall S, et al. 2016 European guidelines on cardiovascular disease prevention in clinical practice. The Sixth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of 10 societies and by invited experts). Developed with the special contribution of the European Association for Cardiovascular Prevention & Rehabilitation (EACPR). Eur Heart J 2016;37:2315-81
- Lloyd-Jones DM, Morris PB, Ballantyne CM, et al. 2016 ACC expert consensus decision pathway on the role of non-statin therapies for LDL-cholesterol lowering in the management of atherosclerotic cardiovascular disease risk: a report of the American College of Cardiology Task Force on Clinical Expert Consensus Documents. J Am Coll Cardiol 2016;68:92-125
- Landmesser U, Chapman MJ, Stock JK, et al. 2017 update of ESC/EAS Task Force on practical clinical guidance for proprotein convertase subtilisin/kexin type 9 inhibition in patients with atherosclerotic cardiovascular disease or in familial hypercholesterolaemia. Eur Heart J 2017;16. DOI: 10.1093/eurheartj/ehx549